Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?
One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.
One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.
What's Your Reaction?
